London, UK, 20th September 2024: PharmaVentures is pleased to announce the appointment of Angela Acosta as the new Director of Pricing and Market Access. Angela joins the team to enhance PharmaVentures’ growing capabilities in providing strategic support for clients looking to bring their products successfully to market.  

Angela brings over a decade of experience in the pharmaceutical industry, specialising in Pricing and Market Access. With her background as a qualified pharmacist, she has worked across both hospital and community settings in the UK before transitioning to her current focus in Market Access.  

Throughout her career, she has played a pivotal role in shaping market strategies, developing tailored messaging for payers and key opinion leaders (KOLs), and delivering innovative solutions to clients. Her expertise spans global markets, including the US, Canada, the EU5, and the GCC, where she has guided big pharma and small-to-medium biotech companies in preparing for commercial success.  

Angela’s experience includes preparing submissions to the Spanish REvalMed for the evaluation of several central nervous system (CNS) therapies. This work involved the creation of detailed submission dossiers and the adaptation of global budget impact and cost-effectiveness models.  

Her wealth of experience and deep understanding of market dynamics will further strengthen PharmaVentures’ ability to provide world-class Pricing and Market Access support to its global clients.

Dr Fintan Walton, CEO of PharmaVentures, said, “ I am delighted to have Angela on board. She is the perfect person to help us to continue to grow our pricing and market practice. With Angela, we are strengthening our capabilities in this area that is so important to dealmaking and strategic decision making in drug development. Welcome Angela.”

– Ends –

For further information, please contact: 

Ralph Hughes 

Senior Vice President, PharmaVentures, Ltd. 
ralph@pharmaventures.com 

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide. 

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest. 

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access 

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

London, UK, 8th August 2024: PharmaVentures is pleased to announce the appointment of Soren Demin as Managing Director and Head of M&A.

Soren’s successful industry and investment banking career, combined with his advisory and medical background, is crucial for understanding clients’ needs and providing optimized solutions. Before this role, Soren served as Chief Business Officer at the Private Equity-backed Essential Pharma. He also held the position of Commercial Director at the UK government’s biological manufacturing unit, Porton BioPharma, where he established new strategic collaborations, directed product development and manufacturing. Previously, Soren was part of Mitsubishi Tanabe Pharma Corporation and the Piramal Group.

Soren embarked on his M&A career with Goldman Sachs, focusing on cross-border deal origination across the US, MENA, Europe, and Asia, before which he studied for a Bachelor of Medicine at the University of Sheffield and a PhD in Biotechnology from the University of Cambridge.”

“I am excited to be joining the PharmaVentures team at this exciting time,” said Soren Demin “So far in 2024 healthcare mergers and acquisitions have surged, with 29 transactions recorded in Q1 alone. The biopharma sector continues to be the main driver representing ~45% of deal volume, with a focus in oncology and inflammation/immunology. Yet despite the challenges such as rising inflation, interest rates, and labour costs, I still anticipate an ongoing global growth and a move to sustainability, through consolidation will drive the Q3/Q4 M&A landscape. Working at PharmaVentures will enable me to help unlock and deliver this added value for our clients”

Dr Fintan Walton, Founder and CEO of PharmaVentures, said, “We are delighted to welcome Soren to PharmaVentures. He has significant experience in all areas of healthcare transactions including Strategy, M&A, Licensing, and fund raising.”

If you would like to learn more about how Soren and PharmaVentures can help your organisation, contact him at soren@pharmaventures.com

– Ends –

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/

London, UK, 20 September 2023: PharmaVentures is pleased to announce it recently acted as exclusive M&A advisor on the sale of a European pharmaceutical services operation to a US corporation.

PharmaVentures led the complete sale process right through to closing. Both parties to the deal have chosen not to announce it publicly.

The sale is one of a number that PharmaVentures has completed in recent years and in a sector where it continues to excel including advising major pharmaceutical companies in the divestment of their manufacturing operations to key players in the pharmaceutical services sector.

The pharmaceutical services sector that includes CROs, CDMOs and other specialist consultancies has been undergoing significant change over recent years. Both new technological advances and the drive to reduce costs continue to provide an opportunity for both private equity and specialist companies to grow and diversify as the pharmaceutical industry evolves.

“This transaction highlights our track record in supporting the sale of specialist pharmaceutical services companies in the pharmaceutical industry,” said Dr Fintan Walton, CEO and Founder of PharmaVentures. “Our decades of experience in M&A, together with our detailed knowledge of the pharmaceutical services industry enabled us to deliver the optimal deal for our client.”

– Ends –

For further information, please contact:

Lisa Holloway
Snr Marketing Manager
lisa@pharmaventures.com

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/

London, UK, 6 September 2023: PharmaVentures is pleased to announce that it acted as the exclusive advisor to Douglas Pharmaceuticals on its U.S. license agreement with Daré Bioscience, Inc. (NASDAQ: DARE) to develop and commercialise R-131-2, a novel topical medicinal candidate for the treatment for cervical intraepithelial neoplasia.

Under the agreement with Douglas Pharmaceuticals, Daré Bioscience will be responsible for advancing the development of R-131-2 in the U.S. while Douglas Pharmaceuticals will retain rights in other territories. Douglas Pharmaceuticals will also support the further development of the product and regulatory package and manufacture the drug for clinical and commercial supply.

Stephen Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted Douglas in finding a suitable U.S. partner for the development and commercialisation of R-131-2 and excited for the potential impact this pharmacological treatment can have on women affected with these conditions. We look forward to helping Douglas with more partnerships for R-131-2.”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported our long-standing client, Douglas Pharmaceuticals, through the discussion with Daré Bioscience. This is yet another exciting example of how PharmaVentures can help clients reach their partnering goals.”

– Ends –

For further information, please contact:

Stephen Waterman
Managing Director
stephen@pharmaventures.com

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

•  M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/

About Douglas Pharmaceuticals

Douglas Pharmaceuticals is New Zealand’s largest privately owned pharmaceutical and healthcare company. It was founded in 1967 by pharmacist Sir Graeme Douglas and today employs over 700 people and exports to over 40 countries around the world.

The Douglas mission is to ‘Improve Lives’ by providing innovative, competitive, and high-quality healthcare solutions. Douglas’ core business is producing prescription drugs for areas including oncology, dermatology, the central nervous system, and immunology. Douglas develops, manufactures, and distributes novel and generic products, with a preference for those where there is a strong intellectual property position as well as technical complexity in areas of high unmet need.

Furthermore, as of Sep 2022 a state-of-the-art research and development facility has opened in West Auckland, which aims to use world class medical research to find solutions for a range of serious illnesses. The $50MM Douglas Innovation centre is part of the long-established Douglas campus in Auckland. The three story, 4,500sq metre building was 18 months in construction. It employs 100 people and includes laboratory, pilot scale product development suites, commercial manufacturing rooms which can handle highly potent and cytotoxic products, and office space. Manufacturing capabilities include soft gelatine encapsulation, liquids, creams, and modified release oral dosage forms.

For more information, please visit: www.douglas.co.nz

London, UK, 11 July 2023: PharmaVentures congratulates GeneCode on their successful application to the European Innovation Council (EIC) Accelerator, securing a groundbreaking funding package of €16 million. The funding comprises €1.7 million in grant funding and €14.3 million in equity investments, marking a significant milestone as the largest funding ever received by an Estonian company under the EIC Accelerator programme.

PharmaVentures is pleased to have supported GeneCode’s highly successful application by providing comprehensive market analysis, deal benchmarking, and asset valuation services.

Stephen Waterman, Managing Director at PharmaVentures, emphasised the importance of a specialised approach, stating, “It is often easy to generalise when discussing larger, unaddressed markets, such as disease modifying therapies for Parkinson’s. However, GeneCode’s achievement demonstrates the tangible value that can be derived from a thorough, detailed, and specific analysis. At PharmaVentures, we pride ourselves on our commitment to delivering in-depth insights that help drive our clients’ success.”

GeneCode’s CEO, Paavo Pilv, expressed his approval of the PharmaVentures analysis, stating, “PharmaVentures has been exceptional throughout the entire process. We greatly appreciated their meticulous care and attention to detail, which is not always found in such collaborations. We look forward to continuing the collaboration with PharmaVentures.”

PharmaVentures recognises the significance of the EIC Accelerator, a highly respected programme under Horizon Europe, supporting cutting-edge innovation and growth in Europe’s entrepreneurial ecosystem.

GeneCode’s groundbreaking treatment for Parkinson’s disease addresses a critical need, as the disease affects over 10 million people worldwide. While current treatments primarily focus on symptom relief, GeneCode’s GDNF mimetic has demonstrated the potential to slow down disease progression, offering new hope for patients. The secured funding will enable GeneCode to accelerate development, aiming to achieve IND-ready status and initiate clinical trials.

– Ends –

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
lisa@pharmaventures.com

Phone: +44 (0) 1865 332700

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/

About GeneCode

GeneCode is a private pharmaceutical development company focused on the development of disease modifying therapeutics to combat neurodegeneration. The company was founded in 1998 in Estonia. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.

More information: www.GeneCode.com
Genecode’s press release can be found here
Genecode website: https://www.genecode.com/news/